In addition, it has been reported that inhibition of IL-17A could enhance the anti-tumor immune response in melanoma and lung cancer [10, 11]; thus, it is possible that targeting of IL-17A suppresses tumor growth in ER-positive breast cancer. This evidence concerns the gene IL17A and lung carcinoma.